177 related articles for article (PubMed ID: 21751955)
1. Use of monoclonal antibodies in renal transplantation.
van den Hoogen MW; Hilbrands LB
Immunotherapy; 2011 Jul; 3(7):871-80. PubMed ID: 21751955
[TBL] [Abstract][Full Text] [Related]
2. Anti-interleukin-2 receptor antibodies for the prevention of rejection in pediatric renal transplant patients: current status.
Swiatecka-Urban A
Paediatr Drugs; 2003; 5(10):699-716. PubMed ID: 14510627
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group.
Vincenti F; Kirkman R; Light S; Bumgardner G; Pescovitz M; Halloran P; Neylan J; Wilkinson A; Ekberg H; Gaston R; Backman L; Burdick J
N Engl J Med; 1998 Jan; 338(3):161-5. PubMed ID: 9428817
[TBL] [Abstract][Full Text] [Related]
4. Antibody induction therapy in renal transplant patients receiving calcineurin-inhibitor immunosuppressive regimens: a comparative review.
Nashan B
BioDrugs; 2005; 19(1):39-46. PubMed ID: 15691216
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-2 receptor monoclonal antibodies in renal transplantation: meta-analysis of randomised trials.
Adu D; Cockwell P; Ives NJ; Shaw J; Wheatley K
BMJ; 2003 Apr; 326(7393):789. PubMed ID: 12689974
[TBL] [Abstract][Full Text] [Related]
6. Is there any role for antithymocyte induction in renal transplantation?
Neidlinger NA; Sollinger HW
Transplant Proc; 2010 Jun; 42(5):1402-7. PubMed ID: 20620444
[TBL] [Abstract][Full Text] [Related]
7. The interleukin-2 inhibitors and their role in low-toxicity regimens.
Nashan B
Transplant Proc; 1999 Dec; 31(8A):23S-26S. PubMed ID: 10616557
[No Abstract] [Full Text] [Related]
8. Prevention of rejection in cardiac transplantation by blockade of the interleukin-2 receptor with a monoclonal antibody.
Beniaminovitz A; Itescu S; Lietz K; Donovan M; Burke EM; Groff BD; Edwards N; Mancini DM
N Engl J Med; 2000 Mar; 342(9):613-9. PubMed ID: 10699160
[TBL] [Abstract][Full Text] [Related]
9. A randomized, placebo-controlled trial with anti-interleukin-2 receptor antibody for immunosuppressive induction therapy after liver transplantation.
Langrehr JM; Glanemann M; Guckelberger O; Klupp J; Neumann U; Machens C; Lohmann R; Knoop M; Lobeck H; Schlag H; Keck H; Settmacher U; Bechstein WO; Neuhaus PJ
Clin Transplant; 1998 Aug; 12(4):303-12. PubMed ID: 9686324
[TBL] [Abstract][Full Text] [Related]
10. [Monoclonal interleukin-2 receptor antibodies and their use in clinical kidney transplantation: basiliximab and daclizumab].
Madsen M; Svendsen UG
Ugeskr Laeger; 2000 Oct; 162(42):5648-52. PubMed ID: 11059309
[TBL] [Abstract][Full Text] [Related]
11. Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation.
Cherikh WS; Kauffman HM; McBride MA; Maghirang J; Swinnen LJ; Hanto DW
Transplantation; 2003 Nov; 76(9):1289-93. PubMed ID: 14627905
[TBL] [Abstract][Full Text] [Related]
12. [Daclizumab and basiliximab: monoclonal mouse-man antibodies with effective immunosuppression without side effects].
ter Meulen CG; Hilbrands LB; van Riemsdijk-van Overbeeke IC; Hené RJ; Christiaans MH; Hoitsma AJ
Ned Tijdschr Geneeskd; 2000 Dec; 144(50):2396-400. PubMed ID: 11145094
[TBL] [Abstract][Full Text] [Related]
13. Induction immunotherapy with IL-2Ra monoclonal antibody in kidney transplantation.
Ahsan N
Minerva Urol Nefrol; 2003 Mar; 55(1):67-79. PubMed ID: 12773968
[TBL] [Abstract][Full Text] [Related]
14. Induction therapy: why, when, and which agent?
Krischock L; Marks SD
Pediatr Transplant; 2010 May; 14(3):298-313. PubMed ID: 20345609
[TBL] [Abstract][Full Text] [Related]
15. Selective unresponsiveness to beta cell autoantigens after induction immunosuppression in pancreas transplantation with anti-interleukin-2 receptor antibody versus anti-thymocyte globulin.
van de Linde P; Vd Boog PJ; Tysma OM; Elliott JF; Roelen DL; Claas FH; de Fijter JW; Roep BO
Clin Exp Immunol; 2007 Jul; 149(1):56-62. PubMed ID: 17459076
[TBL] [Abstract][Full Text] [Related]
16. The clinical application of monoclonal antibody therapies in renal transplantation.
Dhanireddy KK; Xu H; Mannon RB; Hale DA; Kirk AD
Expert Opin Emerg Drugs; 2004 May; 9(1):23-37. PubMed ID: 15155134
[TBL] [Abstract][Full Text] [Related]
17. Extended daclizumab monotherapy for rejection-free survival in non-adherent adolescent recipients of renal allografts.
Chaudhuri A; Salvatierra O; Sarwal MM
Pediatr Transplant; 2009 Nov; 13(7):927-32. PubMed ID: 19017291
[TBL] [Abstract][Full Text] [Related]
18. Role of anti-interleukin-2 receptor antibodies in kidney transplantation.
Cibrik DM; Kaplan B; Meier-Kriesche HU
BioDrugs; 2001; 15(10):655-66. PubMed ID: 11604047
[TBL] [Abstract][Full Text] [Related]
19. Prophylactic use of monoclonal anti-IL-2 receptor antibody in cadaveric renal transplantation.
Carpenter CB; Kirkman RL; Shapiro ME; Milford EL; Tiney NL; Waldmann TA; Zimmerman CE; Ramos EL; Strom TB
Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):54-7. PubMed ID: 2683758
[TBL] [Abstract][Full Text] [Related]
20. Incidence and impact of acute rejection episodes on short- and long-term graft survival in recipients of simultaneous pancreas-kidney transplantation.
Cantarovich D; Giral M; Josien R; Karam G; Hourmant M; Dantal J; Blancho G; Soulillou JP
Transplant Proc; 1995 Feb; 27(1):1319. PubMed ID: 7878897
[No Abstract] [Full Text] [Related]
[Next] [New Search]